Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas.
Benedetta SonegoAdalberto IbaticiGiulia RivoliEmanuele AngelucciSimona SolaCesare MassonePublished in: Cells (2023)
In recent years, targeted (biological) therapies have become available also for primary cutaneous T-cell lymphomas (PCTCLs) including anti-CD30 (brentuximab vedotin) in mycosis fungoides, primary cutaneous anaplastic large T-cell lymphoma, lymphomatoid papulosis; anti-CCR4 (mogamulizumab) in Sezary syndrome; anti-CD123 (tagraxofusp) in blastic plasmocytoid cell neoplasm. Moreover, anti-PD1 (nivolumab), anti-PDL1 (pembrolizumab, atezolizumab), anti-CD52 (alemtuzumab), anti-KIR3DL2-CD158k (lacutamab), and anti-CD70 (cusatuzumab) have been tested or are under investigations in phase II trials. The expression of these epitopes on neoplastic cells in skin biopsies or blood samples plays a central role in the management of PCTCL patients. This narrative review aims to provide readers with an update on the latest advances in the newest therapeutic options for PCTCLs.
Keyphrases
- clinical trial
- phase ii
- ejection fraction
- newly diagnosed
- end stage renal disease
- nk cells
- immune response
- mesenchymal stem cells
- oxidative stress
- single cell
- prognostic factors
- cell proliferation
- open label
- bone marrow
- low grade
- drug delivery
- study protocol
- advanced non small cell lung cancer
- cell therapy
- patient reported outcomes
- wound healing
- epidermal growth factor receptor